IVF and the exogenous progesterone-free luteal phase.
Journal
Current opinion in obstetrics & gynecology
ISSN: 1473-656X
Titre abrégé: Curr Opin Obstet Gynecol
Pays: England
ID NLM: 9007264
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
pubmed:
5
1
2021
medline:
16
10
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
In a conventional IVF cycle, final oocyte maturation and ovulation is triggered with a bolus of hCG, followed by progesterone-based luteal support that spans several weeks if pregnancy is achieved. This article summarizes several approaches of the exogenous progesterone-free luteal support in IVF. Triggering ovulation with GnRH agonist may serve as an alternative to hCG, with well established advantages. In addition, the luteal phase can be individualized in order to achieve a more physiologic hormonal milieu, and a more patient friendly treatment, alleviating the burden of a lengthy exogenous progesterone therapy. GnRH agonist trigger followed by a 'freeze all' policy is undoubtedly the best approach towards the 'OHSS-free clinic'. If fresh embryo transfer is considered well tolerated after GnRH agonist trigger, rescue of the corpora lutea by LH activity supplementation is mandatory. Herein we discuss the different approaches of corpus luteum rescue.
Identifiants
pubmed: 33394734
doi: 10.1097/GCO.0000000000000682
pii: 00001703-202106000-00008
doi:
Substances chimiques
Chorionic Gonadotropin
0
Gonadotropin-Releasing Hormone
33515-09-2
Progesterone
4G7DS2Q64Y
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
188-195Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Tavaniotou A, Devroey P. Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles. Reprod Biomed Online 2006; 13:326–330.
Tavaniotou A, Albano C, Smitz J, Devroey P. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. Hum Reprod 2001; 16:663–667.
Casper RF, Yen SS. Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor. Science 1979; 205:408–410.
Humaidan P, Bungum L, Bungum M, et al. Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol. Reprod Biomed Online 2005; 11:679–684.
Vuong LN, Ho TM, Pham TD, et al. The early luteal hormonal profile in IVF patients triggered with hCG. Hum Reprod 2020; 35:157–166.
Wilcox AJ, Baird DD, Weinberg CR. Time of implantation of the conceptus and loss of pregnancy. N Engl J Med 1999; 340:1796–1799.
Groome NP, Illingworth PJ, O’Brien M, et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996; 81:1401–1405.
Stewart DR, Overstreet JW, Nakajima ST, Lasley BL. Enhanced ovarian steroid secretion before implantation in early human pregnancy. J Clin Endocrinol Metab 1993; 76:1470–1476.
Ubaldi F, Bourgain C, Tournaye H, et al. Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase. Fertil Steril 1997; 67:521–526.
Thomsen LH, Kesmodel US, Erb K, et al. The impact of luteal serum progesterone levels on live birth rates-a prospective study of 602 IVF/ICSI cycles. Hum Reprod 2018; 33:1506–1516.
Eppig JJ. FSH stimulates hyaluronic acid synthesis by oocyte-cumulus cell complexes from mouse preovulatory follicles. Nature 1979; 281:483–484.
Strickland S, Beers WH. Studies on the role of plasminogen activator in ovulation. In vitro response of granulosa cells to gonadotropins, cyclic nucleotides, and prostaglandins. J Biol Chem 1976; 251:5694–5702.
Yding Andersen C. Effect of FSH and its different isoforms on maturation of oocytes from preovulatory follicles. Reprod Biomed Online 2002; 5:232–239.
Godard NM, Pukazhenthi BS, Wildt DE, Comizzoli P. Paracrine factors from cumulus-enclosed oocytes ensure the successful maturation and fertilization in vitro of denuded oocytes in the cat model. Fertil Steril 2009; 91: (5 Suppl): 2051–2060.
D’Alessandris C, Canipari R, Di Giacomo M, et al. Control of mouse cumulus cell-oocyte complex integrity before and after ovulation: plasminogen activator synthesis and matrix degradation. Endocrinology 2001; 142:3033–3040.
Lamb JD, Shen S, McCulloch C, et al. Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2011; 95:1655–1660.
Goldrat O, Gervy C, Englert Y, et al. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients. Hum Reprod 2015; 30:2184–2189.
Uyanik E, Polat M, Mumusoglu S, et al. A drop in serum progesterone levels on day of fresh blastocyst transfer, using standard luteal phase support is associated with significantly lower ongoing pregnancy rates. Abstract, ESHRE. 2020. O-013.
Simón C, Cano F, Valbuena D, et al. Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients. Hum Reprod 1995; 10:2432–2437.
Pellicer A, Valbuena D, Cano F, et al. Lower implantation rates in high responders: evidence for an altered endocrine milieu during the preimplantation period. Fertil Steril 1996; 65:1190–1195.
Thomsen LH, Kesmodel US, Andersen CY, Humaidan P. Daytime variation in serum progesterone during the mid-luteal phase in women undergoing in vitro fertilization treatment. Front Endocrinol (Lausanne) 2018; 9:92.
Mitwally MF, Diamond MP, Abuzeid M. Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization-embryo transfer. Fertil Steril 2010; 93:554–569.
IVF Worldwide: an updated survey: the use of progesterone for luteal phase. 2012. Available at: https://ivf-worldwide.com/survey/an-updated-survey-on-the-use-of-progesterone-for-luteal-phase-support-in-stimulated-ivf-cycles/results-an-updated-survey-on-the-use-of-progesterone-for-luteal-phase-support-in-stimulated-ivf-cycles.html . [Accessed December 11, 2020].
Segal L, Breyzman T, Kol S. Luteal phase support post IVF: individualized early stop. Reprod Biomed Online 2015; 31:633–637.
Nyboe Andersen A, Popovic-Todorovic B, Schmidt KT, et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Hum Reprod 2002; 17:357-361.
Humaidan P, Kol S. Papanikolaou EG; Copenhagen GnRH Agonist Triggering Workshop Group.GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 2011; 17:510–524.
Castillo JC, Haahr T, Martínez-Moya M, Humaidan P. Gonadotropin-releasing hormone agonist ovulation trigger-beyond OHSS prevention. Ups J Med Sci 2020; 125:138–143.
Nevo O, Eldar-Geva T, Kol S, Itskovitz-Eldor J. Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Fertil Steril 2003; 79:1123–1128.
Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004; 81:1–5.
Devroey P, Polyzos NP, Blockeel C. An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod 2011; 26:2593–2597.
Castillo JC, Haahr T, Martínez-Moya M, Humaidan P. Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer. Ups J Med Sci 2020; 125:131–137.
Humaidan P, Polyzos NP, Alsbjerg B, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multicentre studies in IVF patients. Hum Reprod 2013; 28:2511–2521.
Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010; 93:847–854.
Benmachiche A, Benbouhedja S, Zoghmar A, et al. Impact of mid-luteal phase GnRH agonist administration on reproductive outcomes in GnRH agonist-triggered cycles: a randomized controlled trial. Front Endocrinol (Lausanne) 2017; 8:124.
Oktay K, Türkçüoğlu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 2010; 20:783–788.
Erb TM, Vitek W, Wakim AN. Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program. Fertil Steril 2010; 93:374–378.
Reddy J, Turan V, Bedoschi G, et al. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet 2014; 31:927–932.
Pereira N, Kelly AG, Stone LD, et al. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation. Fertil Steril 2017; 108:532–538.
Vuong TN, Ho MT, Ha TD, et al. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. Fertil Steril 2016; 105:356–363.
Tannus S, Burke Y, McCartney CR, Kol S. GnRH-agonist triggering for final oocyte maturation in GnRH-antagonist IVF cycles induces decreased LH pulse rate and amplitude in early luteal phase: a possible luteolysis mechanism. Gynecol Endocrinol 2017; 33:741–745.
Humaidan P, Bredkjaer HE, Bungum L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005; 20:1213–1220.
Filicori M, Butler JP, Crowley WF Jr. Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion. J Clin Invest 1984; 73:1638–1647.
Kol S, Breyzman T, Segal L, Humaidan P. ’Luteal coasting’ after GnRH agonist trigger - individualized, HCG-based, progesterone-free luteal support in ’high responders’: a case series. Reprod Biomed Online 2015; 31:747–751.
Kol S, Humaidan P, Itskovitz-Eldor J. GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study. Hum Reprod 2011; 26:2874–2877.
Andersen CY, Elbaek HO, Alsbjerg B, et al. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial. Hum Reprod 2015; 30:2387–2395.
Pirard C, Donnez J, Loumaye E. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum Reprod 2005; 20:1798–1804.
Pirard C, Loumaye E, Laurent P, Wyns C. Contribution to more patient-friendly art treatment: efficacy of continuous low-dose GnRH agonist as the only luteal support-results of a prospective, randomized, comparative study. Int J Endocrinol 2015; 2015:727569.
Bar-Hava I, Mizrachi Y, Karfunkel-Doron D, et al. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders. Fertil Steril 2016; 106:330–333.
Bar Hava I, Yafee H, Omer Y, et al. GnRHa for trigger and luteal phase support in natural cycle frozen embryo transfer - a proof of concept study. Reprod Biol 2020; 20:282–287.
Vanetik S, Segal L, Breizman T, Kol S. Day two post retrieval 1500 IUI hCG bolus, progesterone-free luteal support post GnRH agonist trigger – a proof of concept study. Gynecol Endocrinol 2017; 34:132–135.
Kol S, Segal L. GnRH agonist triggering followed by 1500 IU of hCG 48 h post oocyte retrieval for luteal phase support. Reprod Biomed Online 2020; 41:854–858.